Subscriber Content Preview | Request a free trialSearch  
  Go

Entries tagged "Tysabri"

You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "Tysabri."

5 result(s) displayed (1 - 5 of 5)


Stage set for showdown over Elan

Eyes are on Royal Pharma as it weighs its best and final offer. Continue reading

Posted on April 19, 2013 9:05 AM




Royalty Pharma makes $6.5B unsolicited bid for Elan

The pharmaceuticals investor discloses its bid plan after hitting a roadblock in talks with the Irish drugmaker. Continue reading

Posted on February 25, 2013 8:48 AM




Elan outlines how it will use Tysabri sale proceeds

The Irish drugmaker will take the opportunity after the $3.25 billion sale of the multiple sclerosis treatment to make acquisitions, buy shares and refinance its debt. Continue reading

Posted on February 22, 2013 4:27 PM




Biogen buys out Tysabri rights for $3.3B

Elan cedes control of the blockbuster multiple sclerosis drug, its sole revenue producer, in an attempt to pursue a new strategic direction through acquisitions. Continue reading

Posted on February 6, 2013 11:23 AM




After drug's collapse, all eyes on Elan

The pharmaceutical company's share price is buoyed by takeover speculation after its Alzheimer's compound fails a clinical trial Continue reading

Posted on August 8, 2012 9:08 AM






Movable Type search results powered by Fast Search



Popular tags




Movers & Shakers

Launch Movers and shakers slideshow

Ken deRegt will retire as head of fixed income at Morgan Stanley and be replaced by Michael Heaney and Robert Rooney. For other updates launch today's Movers & shakers slideshow.

Video

Coming back for more

Apax Partners offers $1.1 billion for Rue21, the same teenage fashion chain it took public in 2009. More video

Sectors